[go: up one dir, main page]

MX2007004861A - Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias. - Google Patents

Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.

Info

Publication number
MX2007004861A
MX2007004861A MX2007004861A MX2007004861A MX2007004861A MX 2007004861 A MX2007004861 A MX 2007004861A MX 2007004861 A MX2007004861 A MX 2007004861A MX 2007004861 A MX2007004861 A MX 2007004861A MX 2007004861 A MX2007004861 A MX 2007004861A
Authority
MX
Mexico
Prior art keywords
glucocorticoid receptor
treatment
inflammatory diseases
receptor modulators
sulphonamide derivatives
Prior art date
Application number
MX2007004861A
Other languages
English (en)
Inventor
Matti Lepisto
Hakan Bladh
Krister Henriksson
Vijaykumar Hulikal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2007004861A publication Critical patent/MX2007004861A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describe un compuesto de la formula (I) o una sal farmaceuticamente aceptable del mismo, composiciones que los comprende, procesos para prepararlos y sus uso en terapias medicas (por ejemplo modular el receptor glucocorticoide en un animal de sangre caliente).
MX2007004861A 2004-10-29 2005-10-26 Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias. MX2007004861A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0402635A SE0402635D0 (sv) 2004-10-29 2004-10-29 Chemical compounds
PCT/SE2005/001608 WO2006046914A1 (en) 2004-10-29 2005-10-26 Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2007004861A true MX2007004861A (es) 2007-05-09

Family

ID=33448752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004861A MX2007004861A (es) 2004-10-29 2005-10-26 Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.

Country Status (21)

Country Link
US (1) US20110130426A1 (es)
EP (1) EP1807405A1 (es)
KR (1) KR20070072550A (es)
CN (1) CN101052627A (es)
AR (1) AR051471A1 (es)
AU (1) AU2005300148A1 (es)
BR (1) BRPI0517259A (es)
CA (1) CA2584409A1 (es)
EC (1) ECSP077323A (es)
GT (1) GT200500306A (es)
IL (1) IL182424A0 (es)
MX (1) MX2007004861A (es)
PA (1) PA8651101A1 (es)
PE (1) PE20060931A1 (es)
RS (1) RS20070077A (es)
RU (1) RU2007115548A (es)
SE (1) SE0402635D0 (es)
TW (1) TW200630352A (es)
UY (1) UY29181A1 (es)
WO (1) WO2006046914A1 (es)
ZA (1) ZA200703389B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2009129267A2 (en) 2008-04-14 2009-10-22 The Board Of Regents Of The University Of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
TWI445705B (zh) 2008-05-20 2014-07-21 Astrazeneca Ab 經苯基及苯并二基取代之吲唑衍生物
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP6249966B2 (ja) 2012-02-29 2017-12-20 ケモセントリックス， インコーポレイテッド アザ−アリール１ｈ−ピラゾール−１−イルベンゼンスルホンアミド
MX372739B (es) 2012-12-14 2020-05-06 Phusis Therapeutics Inc Metodos y composiciones para inhibir cnksr1.
WO2016057424A1 (en) 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
US10227317B2 (en) 2015-02-25 2019-03-12 Lupin Limited Process for the preparation of vortioxetine
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
CN111989325B (zh) 2018-04-18 2025-02-25 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP4003532B1 (en) 2019-07-24 2024-09-04 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444347A (en) * 1891-01-06 James
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
DE3535167A1 (de) * 1985-10-02 1987-04-09 Boehringer Mannheim Gmbh Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
AU5772296A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1999038845A1 (en) * 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
US6569885B1 (en) * 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EP1432693A2 (en) * 2001-10-01 2004-06-30 Taisho Pharmaceutical Co. Ltd. Mch receptor antagonists
NZ536504A (en) * 2002-05-24 2008-04-30 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
EP2415760A3 (en) * 2003-02-20 2012-02-22 Encysive Pharmaceuticals, Inc. CCR-9 antagonists
EP1643960A2 (en) * 2003-07-02 2006-04-12 Merck & Co., Inc. Arylsulfonamide derivatives
JP2007527918A (ja) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Ｐｐａｒガンマ活性の治療的調節

Also Published As

Publication number Publication date
CN101052627A (zh) 2007-10-10
PE20060931A1 (es) 2006-10-13
BRPI0517259A (pt) 2008-10-07
UY29181A1 (es) 2006-05-31
CA2584409A1 (en) 2006-05-04
RS20070077A (sr) 2008-09-29
US20110130426A1 (en) 2011-06-02
ECSP077323A (es) 2007-04-26
PA8651101A1 (es) 2006-06-02
TW200630352A (en) 2006-09-01
WO2006046914A1 (en) 2006-05-04
AU2005300148A1 (en) 2006-05-04
IL182424A0 (en) 2007-07-24
GT200500306A (es) 2006-06-06
EP1807405A1 (en) 2007-07-18
KR20070072550A (ko) 2007-07-04
AR051471A1 (es) 2007-01-17
SE0402635D0 (sv) 2004-10-29
RU2007115548A (ru) 2008-12-10
ZA200703389B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
NO20065904L (no) Terapeutiske forbindelser
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
MX2007004861A (es) Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias.
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
GEP20125379B (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
UA86977C2 (ru) Производные гидантоина для лечения обструктивных болезней дыхательных путей
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
TW200639156A (en) New compounds
TW200610761A (en) Chemical compounds
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
SE0301369D0 (sv) Chemical compounds
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
PT2234966E (pt) Derivados de azetidinas, sua preparação e sua aplicação em terapia
SE0401657D0 (sv) Chemical compounds
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
SE0402636D0 (sv) Chemical compounds
IL181666A0 (en) Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof
TW200606148A (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands
DE602005001918D1 (de) S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers

Legal Events

Date Code Title Description
FA Abandonment or withdrawal